Cytokinetics Inc Stock Price, News & Analysis

Cytokinetics (CYTK) has announced its Annual Meeting of Stockholders, scheduled for Wednesday, May 14, 2025, at 10:00 AM Pacific Time. The meeting will be held at the company's headquarters in South San Francisco. Following the meeting, CEO Robert I. Blum will present a company update.

Stockholders of record as of March 24, 2025 are eligible to vote and attend in person. Voting options include in-person attendance or proxy submission via mail, telephone, or internet by 11:59 PM Eastern Time on May 13, 2025. The meeting will be available via live webcast, with a replay accessible through the company's website for twelve months.

Cytokinetics (NASDAQ: CYTK) reported Q1 2025 financial results and business updates. Key highlights include: FDA extended the PDUFA date for aficamten in obstructive HCM to December 26, 2025, following a REMS submission. The company maintains $1.1 billion in cash as of March 31, 2025. Financial results show Q1 2025 net loss of $161.4 million ($1.36 per share) compared to $135.6 million in Q1 2024. Revenue was $1.6 million, up from $0.8 million year-over-year. R&D expenses increased to $99.8 million from $81.6 million, while G&A expenses rose to $57.4 million from $45.5 million. The company completed enrollment in ACACIA-HCM trial ahead of schedule and expects topline results from MAPLE-HCM in May 2025. Cytokinetics maintains its 2025 guidance with GAAP operating expenses projected between $670-710 million.

Cytokinetics (CYTK) announced that the FDA has extended the PDUFA date for aficamten, its drug candidate for obstructive hypertrophic cardiomyopathy (oHCM), to December 26, 2025. The extension comes after the FDA requested Cytokinetics to submit a Risk Evaluation and Mitigation Strategy (REMS), which was deemed a Major Amendment to the New Drug Application (NDA).

The FDA's decision resulted in a standard three-month extension from the original PDUFA date. Notably, no additional clinical data or studies were requested. The company maintains confidence in aficamten's benefit-risk profile and expects a differentiated label upon potential FDA approval.

Cytokinetics (Nasdaq: CYTK) has announced its participation in two major investor conferences this May. The company will engage in fireside chats at:

• The Citizens Life Sciences Conference on May 7, 2025, at 10:00 AM ET at the New York Hilton Midtown Hotel
• The 2025 RBC Capital Markets Global Healthcare Conference on May 21, 2025, at 8:30 AM ET at the InterContinental New York Barclay Hotel

Both fireside chats will be accessible via live webcasts through the Investors & Media section of Cytokinetics' website. Recordings will remain available for 90 days after the events.

Cytokinetics (CYTK) has announced it will release its first quarter 2025 financial results on May 6, 2025, at 4:00 PM Eastern Time. Following the earnings release, the company's senior management will host a conference call at 4:30 PM Eastern Time to discuss the financial performance and provide business updates.

The conference call will be accessible through a simultaneous webcast from the Investors & Media section of Cytokinetics' website. Participants can also join via telephone by pre-registering through a provided link. A replay of the webcast will remain available on the company's website for six months.

Cytokinetics (CYTK) has announced new inducement grants for 13 employees who joined the company in March and April 2025. The compensation package includes:

- Stock options to purchase 60,670 shares of common stock at $38.56 per share (closing price on April 15, 2025)

- 40,888 restricted stock units (RSUs)

The RSUs will vest over 3 years (40% in year 1, 40% in year 2, 20% in year 3), while stock options vest over 4 years (25% after first year, remaining monthly over 36 months). The stock options have a 10-year term. These grants were made under Nasdaq Listing Rule 5635(c)(4) as material inducements to employment.

Cytokinetics (Nasdaq: CYTK) has announced its upcoming participation in the 24th Annual Needham Virtual Healthcare Conference. The company's management team will engage in a fireside chat scheduled for Monday, April 7, 2025, at 2:15 PM Eastern Time.

Investors and interested parties can access the live webcast through the Investors & Media section of Cytokinetics' website. The webcast recording will remain available on the company's website for 90 days after the event concludes.

Cytokinetics (NASDAQ: CYTK) has launched EARTH-HCM, an innovative online public health education tool focusing on hypertrophic cardiomyopathy (HCM). This interactive platform analyzes real-world, de-identified claims data from over 65,000 pharmacies, 1,500 hospitals, 800 outpatient facilities, and 80,000 physician practices across the U.S.

The tool, developed in collaboration with leading academic institutions, visualizes population differences in patient characteristics, treatments, clinical outcomes, healthcare resource utilization, and costs in HCM. EARTH-HCM aims to serve multiple stakeholders, including patients, clinicians, researchers, policy makers, payors, and advocacy groups.

The platform utilizes Symphony Health's Integrated Dataverse prescription claims database, covering HCM patients diagnosed between 2016 and 2023. Regular updates are planned, with future expansion to include global data.

Cytokinetics (CYTK) has announced new equity compensation grants as inducement awards to 13 new employees who joined in February and March 2025. The grants include:

- 58,631 stock options at $44.36 per share (closing price on March 14, 2025)
- 38,068 restricted stock units (RSUs)
- 3,381 performance stock units (PSUs)

The RSUs will vest over 3 years (40% in year 1, 40% in year 2, 20% in year 3). Stock options will vest over 4 years (25% after year 1, remaining monthly over 36 months) with a 10-year term. PSUs are tied to two performance goals, with 50% of shares earned upon certification of each goal, followed by a two-stage vesting schedule.